The FBXO32 antibody is a research tool targeting FBXO32 (F-box protein 32), also known as Atrogin-1 or MAFbx, a key component of the ubiquitin-proteasome system. FBXO32 functions as a substrate-recognition subunit within the SCF (SKP1-CUL1-F-box protein) E3 ubiquitin ligase complex, directing specific proteins for proteasomal degradation. It plays a critical role in muscle atrophy by ubiquitinating proteins like MyoD and eIF3-f, thereby regulating skeletal muscle mass under conditions such as starvation, disuse, or disease.
FBXO32 is implicated in multiple pathways, including the AKT/mTOR signaling axis, and its expression is upregulated in catabolic states. Beyond muscle biology, it has been linked to cancer progression, neurodegenerative diseases, and cardiac remodeling. The FBXO32 antibody is widely used in Western blotting, immunohistochemistry, and immunofluorescence to study protein expression, localization, and degradation mechanisms in these contexts.
Researchers utilize this antibody to explore FBXO32's role in cellular homeostasis, disease pathogenesis, and therapeutic targeting. Validation methods (e.g., knockout controls) are essential due to potential cross-reactivity with related F-box proteins. Its applications span basic research, drug development, and biomarker studies, particularly in disorders involving protein turnover dysregulation.